# A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT03023423** · PHASE1,PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 100 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT03023423
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-23
- **Primary completion:** 2018-05-17
- **Final completion:** 2019-09-26
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2019-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03023423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03023423, "A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03023423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*